Titan Pharmaceuticals (NASDAQ:TTNP) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP) in a research report released on Wednesday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Stock Performance

TTNP opened at $3.77 on Wednesday. Titan Pharmaceuticals has a 52-week low of $3.03 and a 52-week high of $14.80. The firm has a market cap of $3.44 million, a P/E ratio of -0.72 and a beta of 1.19. The business’s fifty day moving average is $3.69 and its 200-day moving average is $3.94.

Titan Pharmaceuticals (NASDAQ:TTNP) last announced its quarterly earnings data on Thursday, March 20th. The specialty pharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter.

Titan Pharmaceuticals Company Profile

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.